top of page
Search

January 11, 2019

Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clobetasol Propionate Cream USP, 0.05% in the following packaging configurations, 15 g, 30 g, 45 g and 60 g tubes. For more updates, please feel free to email us info@solaris-pharma.com

94 views0 comments

Recent Posts

See All

Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP

bottom of page